NASDAQ:BRTX BioRestorative Therapies Q1 2025 Earnings Report $1.84 +0.05 (+2.50%) Closing price 03:52 PM EasternExtended Trading$1.85 +0.01 (+0.27%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast BioRestorative Therapies EPS ResultsActual EPSN/AConsensus EPS -$0.32Beat/MissN/AOne Year Ago EPSN/ABioRestorative Therapies Revenue ResultsActual RevenueN/AExpected Revenue$0.38 millionBeat/MissN/AYoY Revenue GrowthN/ABioRestorative Therapies Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile BioRestorative Therapies Earnings HeadlinesBioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025May 8, 2025 | globenewswire.comBioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025May 7, 2025 | globenewswire.comAmerica’s secret warWhile the media fixates on tariffs and market noise, something historic is unfolding behind the scenes. With backing from the White House and Silicon Valley billionaires, a vast network of AI-powered facilities is taking shape across the country. They’re being called “Cathedrals of Light” — and they hold the keys to nuclear fusion, advanced medicine, and defense breakthroughs. I’ve spent 25 years identifying seismic shifts like this — and I believe this could be the biggest one yet for early investors.May 12, 2025 | Porter & Company (Ad)EQS-News: BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc DiseaseApril 16, 2025 | markets.businessinsider.comBioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial OpportunitiesApril 15, 2025 | globenewswire.comBioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United StatesApril 10, 2025 | globenewswire.comSee More BioRestorative Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioRestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioRestorative Therapies and other key companies, straight to your email. Email Address About BioRestorative TherapiesBioRestorative Therapies (NASDAQ:BRTX), a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.View BioRestorative Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings JD.com (5/13/2025)NU (5/13/2025)SEA (5/13/2025)Sony Group (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
